Lucid Diagnostics Stock (NASDAQ:LUCD)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.00

52W Range

$0.63 - $1.58

50D Avg

$0.88

200D Avg

$0.91

Market Cap

$53.94M

Avg Vol (3M)

$294.56K

Beta

1.42

Div Yield

-

LUCD Company Profile


Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

70

IPO Date

Oct 14, 2021

Website

LUCD Performance


LUCD Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 13, 24 | 2:44 PM
Q2 24Aug 12, 24 | 1:32 PM
Q1 24May 13, 24 | 12:00 AM

Peer Comparison


TickerCompany
FNAParagon 28, Inc.
IRMDIRadimed Corporation
OFIXOrthofix Medical Inc.
ITGRInteger Holdings Corporation
LUNGPulmonx Corporation
CLPTClearPoint Neuro, Inc.
NPCENeuroPace, Inc.
SRDXSurmodics, Inc.
LIVNLivaNova PLC
KIDSOrthoPediatrics Corp.
OSAProSomnus, Inc. Common Stock
XAIRBeyond Air, Inc.
NARIInari Medical, Inc.
CVRXCVRx, Inc.